Abstract
Molybdenum oxide, as one of the important transition metal semiconductor materials with photothermal property, has received increasing attention in the field of catalysis, sensing, energy storage, and clinical biomedicine. To improve its certain limitations such as poor biocompatibility and easy agglomeration during application as biomaterials and promote its performance as photothermal agent in biomedical fields, polyethylene glycol (PEG)–modified molybdenum oxide was synthesized and the synthesis conditions during the hydrothermal process, including the pH values and the amount of PEG added, were adjusted. Owing to the reduction function of PEG, as-obtained PEG-MoOx showed good photostability and colloidal stability, which were beneficial to its application in long-term clinical photothermal therapy. In addition, cell experiments indicated that PEG-MoOx particles exhibited low cytotoxicity and ability of photothermal killing for HeLa cells. With the increase PEG-MoOx particles in solution, the photothermal ablation ability of PEG-MoOx particles for the HeLa cells was enhanced under an 808-nm NIR laser irradiation. Hence, PEG-MoOx particles have great potential in the photothermal treatment of diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
